Pharmacological regimens for eradication of Helicobacter pylori: An overview of systematic reviews and network meta-analysis

BMC Gastroenterology

Volumn 16, Issue 1, 2016, Pages

  Xin, Yiqiao ^a   Manson, Jan ^b   Govan, Lindsay ^a   Harbour, Robin ^b   Bennison, Jenny ^c   Watson, Eleanor ^d   Wu, Olivia ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b HEALTHCARE IMPROVEMENT SCOTLAND   (United Kingdom)

^c ROYAL COLLEGE OF GENERAL PRACTITIONERS   (United Kingdom)

^d ROYAL INFIRMARY OF EDINBURGH   (United Kingdom)

Author keywords

Eradication; Helicobacter pylori; Network meta analysis; Systematic review

Indexed keywords

AMOXICILLIN; AZITHROMYCIN; BISMUTH; CLARITHROMYCIN; ESOMEPRAZOLE; FAMOTIDINE; FURAZOLIDONE; LAFUTIDINE; LANSOPRAZOLE; LEVOFLOXACIN; METRONIDAZOLE; MOXIFLOXACIN; NITROIMIDAZOLE; NIZATIDINE; OMEPRAZOLE; PANTOPRAZOLE; RABEPRAZOLE; RANITIDINE; RANITIDINE BISMUTH CITRATE; REBAMIPIDE; RIFABUTIN; TETRACYCLINE; TINIDAZOLE; ANTACID AGENT; ANTIINFECTIVE AGENT; HISTAMINE H2 RECEPTOR ANTAGONIST; PROTON PUMP INHIBITOR;

ABDOMINAL PAIN; ABNORMAL FECES; ANTIBIOTIC RESISTANCE; ARTICLE; CHRONIC GASTRITIS; COMORBIDITY; DARK STOOL; DIARRHEA; DISEASE ERADICATION; DISEASE SEVERITY; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; DUODENUM ULCER; DYSPEPSIA; HEADACHE; HEALTH CARE QUALITY; HELICOBACTER INFECTION; HUMAN; INTENTION TO TREAT ANALYSIS; META ANALYSIS; METALLIC TASTE; NAUSEA; PEPTIC ULCER; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMATIC REVIEW; TREATMENT OUTCOME; COMBINATION DRUG THERAPY; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; NETWORK META-ANALYSIS; PRACTICE GUIDELINE;

ANTACIDS; ANTI-BACTERIAL AGENTS; BISMUTH; DRUG THERAPY, COMBINATION; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HISTAMINE H2 ANTAGONISTS; HUMANS; NETWORK META-ANALYSIS; PRACTICE GUIDELINES AS TOPIC; PROTON PUMP INHIBITORS;

EID: 84979247561     PISSN: None     EISSN: 1471230X     Source Type: Journal    
DOI: 10.1186/s12876-016-0491-7     Document Type: Article

References (56)

1. Everhart JE, Kruszon-Moran D, Perez-Perez GI, Tralka TS, McQuillan G. Seroprevalence and ethnic differences in Helicobacter pylori infection among adults in the United States. J Infect Dis. 2000;181:1359-63.
2. Ford AC, Axon AT. Epidemiology of Helicobacter pylori infection and public health implications. Helicobacter. 2010;15 Suppl 1:1-6.
3. Mandeville KL, Krabshuis J, Ladep NG, Mulder CJ, Quigley EM, Khan SA. Gastroenterology in developing countries: issues and advances. World J Gastroenterol. 2009;15:2839-54.
4. Parsonnet J, Hansen S, Rodriguez L, Gelb AB, Warnke RA, Jellum E, et al. Helicobacter pylori infection and gastric lymphoma. N Engl J Med. 1994;330:1267-71.
5. Qadri Q, Rasool R, Gulzar GM, Naqash S, Shah ZA. H. pylori Infection, Inflammation and Gastric Cancer. J Gastrointest Cancer. 2014;45:126-32.
6. Panic N, Mastrostefano E, Leoncini E, Persiani R, Arzani D, Amore R, et al. Susceptibility to Helicobacter pylori infection: results of an epidemiological investigation among gastric cancer patients. Mol Biol Rep. 2014;41:3637-50.
7. Hsu WY, Lin CH, Lin CC, Sung FC, Hsu CP, Kao CH. The relationship between Helicobacter pylori and cancer risk. Eur J Intern Med. 2014;25:235-40.
8. Chen YS, Xu SX, Ding YB, Huang XE, Deng B. Helicobacter pylori Infection and the Risk of Colorectal Adenoma and Adenocarcinoma: an Updated Meta-analysis of Different Testing Methods. Asian Pac J Cancer Prev. 2013;14:7613-9.
9. Peek Jr RM, Fiske C, Wilson KT. Role of innate immunity in Helicobacter pylori-induced gastric malignancy. Physiol Rev. 2010;90:831-58.
10. Gisbert JP, Calvet X, Cosme A, Almela P, Feu F, Bory F, et al. Long-term follow-up of 1,000 patients cured of Helicobacter pylori infection following an episode of peptic ulcer bleeding. Am J Gastroenterol. 2012;107:1197-204.
11. Ford AC, Forman D, Hunt RH, Yuan Y, Moayyedi P. Helicobacter pylori eradication therapy to prevent gastric cancer in healthy asymptomatic infected individuals: systematic review and meta-analysis of randomised controlled trials. BMJ. 2014;348:g3174.
12. Malfertheiner P, Megraud F, O'Morain CA, Atherton J, Axon AT, Bazzoli F, et al. Management of Helicobacter pylori infection--the Maastricht IV/Florence Consensus Report. Gut. 2012;61:646-64.
13. Hunt R, Fallone C, Veldhuyzan van Zanten S, Sherman P, Smaill F, Flook N, et al. Canadian Helicobacter Study Group Consensus Conference: Update on the management of Helicobacter pylori--an evidence-based evaluation of six topics relevant to clinical outcomes in patients evaluated for H pylori infection. Can J Gastroenterol. 2004;18:547-54.
14. Chey WD, Wong BC. American College of Gastroenterology guideline on the management of Helicobacter pylori infection. Am J Gastroenterol. 2007;102:1808-25.
15. National Institute for Health and Care Excellence. Dyspepsia: Managing Dyspepsia in Adults in Primary Care. CG17. London: National Institute for Health and Care Excellence; 2004. Newcastle upon Tyne UK: Crown 2004.
16. Giorgio F, Principi M, De Francesco V, Zullo A, Losurdo G, Di Leo A, et al. Primary clarithromycin resistance to Helicobacter pylori: Is this the main reason for triple therapy failure? World J Gastrointest Pathophysiol. 2013;4:43-6.
17. Sasaki M, Ogasawara N, Utsumi K, Kawamura N, Kamiya T, Kataoka H, et al. Changes in 12-Year First-Line Eradication Rate of Helicobacter pylori Based on Triple Therapy with Proton Pump Inhibitor, Amoxicillin and Clarithromycin. J Clin Biochem Nutr. 2010;47:53-8.
18. Scottish Intercollegiate Guidelines Network (SIGN). Dyspepsia. Edinburgh: SIGN; 2003. SIGN publication no.68.
19. Smith V, Devane D, Begley CM, Clarke M. Methodology in conducting a systematic review of systematic reviews of healthcare interventions. BMC Med Res Methodol. 2011;11:15.
20. Scottish Intercollegiate Guidelines Network (SIGN). Critical appraisal: notes and checklists. http://www.sign.ac.uk/methodology/checklists.html. Accessed 02 Feb 2014.
21. Lumley T. Network meta-analysis for indirect treatment comparisons. Stat Med. 2002;21:2313-24.
22. Mills EJ, Thorlund K, Ioannidis JP. Demystifying trial networks and network meta-analysis. BMJ. 2013;346:f2914.
23. Lunn DJ, Thomas A, Best N, Spiegelhalter D. WinBUGS - A Bayesian modelling framework: Concepts, structure, and extensibility. Stat Comput. 2000;10:325-37.
24. Wang Z, Xiong G, Wu S. Comparing the efficacy of esomeprazole and omeprazole combined with antibiotics in Helicobacter pylori eradication: A meta-analysis. Chin J Gastroenterol. 2006;11:598-601.
25. Zhang ZF, Zhao G, Liu LN. Effectiveness and safety of proton pump inhibitor and levofloxacin based first-line triple therapy in the eradication of Helicobacter pylori: a meta-analysis. Zhonghua Yi Xue Za Zhi. 2008;88:2722-5.
26. Gou QY, Shi RH, Yu RB. Levofloxacin containing triple therapy vs standard triple therapy for eradication of Helicobacter pylori: A Meta-analysis. [Chinese]. Shi Jie Hua Ren Xiao Hua Za Zhi. 2014;22:5207-11.
27. Gisbert JP, Gonzalez L, Calvett X. Systematic review and meta-analysis: Proton pump inhibitor vs. ranitidine bismuth citrate plus two antibiotics in Helicobacter pylori eradication. Helicobacter. 2005;10:157-71.
28. Gisbert JP, De La Morena F. Systematic review and meta-analysis: Levofloxacin-based rescue regimens after Helicobacter pylori treatment failure. Aliment Pharmacol Ther. 2006;23:35-44.
29. Saad RJ, Schoenfeld P, Kim HM, Chey WD. Levofloxacin-based triple therapy versus bismuth-based quadruple therapy for persistent Helicobacter pylori infection: a meta-analysis. Am J Gastroenterol. 2006;101:488-96.
30. Li Y, Huang X, Yao L, Shi R, Zhang G. Advantages of moxifloxacin and levofloxacin-based triple therapy for second-line treatments of persistent Helicobacter pylori infection: a meta analysis. Wien Klin Wochenschr. 2010;122:413-22.
31. Wu C, Chen X, Liu J, Li M-Y, Zhang Z-Q, Wang Z-Q. Moxifloxacin-containing triple therapy versus bismuth-containing quadruple therapy for second-line treatment of Helicobacter pylori infection: a meta-analysis. Helicobacter. 2011;16:131-8.
32. Di Caro S, Fini L, Daoud Y, Grizzi F, Gasbarrini A, De Lorenzo A, et al. Levofloxacin/amoxicillin-based schemes vs quadruple therapy for helicobacter pylori eradication in second-line. World J Gastroenterol. 2012;18:5669-78.
33. Dong J, Yu X-F, Zou J. Azithromycin-containing versus standard triple therapy for Helicobacter pylori eradication: a meta-analysis. World J Gastroenterol. 2009;15:6102-10.
34. Yuan W, Yang K, Ma B, Li Y, Guan Q, Wang D, et al. Moxifloxacin-based triple therapy versus clarithromycin-based triple therapy for first-line treatment of Helicobacter pylori infection: a meta-analysis of randomized controlled trials. Intern Med. 2009;48:2069-76.
35. Ye CL, Liao GP, He S, Pan YN, Kang YB, Zhang ZY. Levofloxacin and proton pump inhibitor-based triple therapy versus standard triple first-line therapy for Helicobacter pylori eradication. Pharmacoepidemiol Drug Saf. 2014;23:443-55.
36. Peedikayil MC, Alsohaibani FI, Alkhenizan AH. Levofloxacin-based first-line therapy versus standard first-line therapy for Helicobacter pylori eradication: meta-analysis of randomized controlled trials. PLoS One. 2014;9:e85620.
37. Xiao SP, Gu M, Zhang GX. Is levofloxacin-based triple therapy an alternative for first-line eradication of Helicobacter pylori? A systematic review and meta-analysis. Scand J Gastroentero. 2014;49:528-38.
38. Gene E, Calvet X, Azagra R, Gisbert JP. Triple vs. quadruple therapy for treating Helicobacter pylori infection: a meta-analysis. Aliment Pharmacol Ther. 2003;17:1137-43.
39. Venerito M, Krieger T, Ecker T, Leandro G, Malfertheiner P. Meta-analysis of bismuth quadruple therapy versus clarithromycin triple therapy for empiric primary treatment of Helicobacter pylori infection. Digestion. 2013;88:33-45.
40. Gisbert JP, Khorrami S, Calvet X, Gabriel R, Carballo F, Pajares JM. Meta-analysis: proton pump inhibitors vs. H2-receptor antagonists--their efficacy with antibiotics in Helicobacter pylori eradication. Aliment Pharmacol Ther. 2003;18:757-66.
41. Ren Q, Ma B, Yang K, Yan X. Lafutidine-based triple therapy for Helicobacter pylori eradication. Hepatogastroenterology. 2010;57:1074-81.
42. McNicholl AG, Linares PM, Nyssen OP, Calvet X, Gisbert JP. Meta-analysis: esomeprazole or rabeprazole vs. first-generation pump inhibitors in the treatment of Helicobacter pylori infection. Aliment Pharmacol Ther. 2012;36:414-25.
43. Gisbert JP, Khorrami S, Calvet X, Pajares JM. Systematic review: Rabeprazole-based therapies in Helicobacter pylori eradication. Aliment Pharmacol Ther. 2003;17:751-64.
44. Gisbert JP, Pajares JM. Esomeprazole-based therapy in Helicobacter pylori eradication: a meta-analysis. Dig Liver Dis. 2004;36:253-9.
45. Gisbert JP, Khorrami S, Calvet X, Pajares JM. Pantoprazole based therapies in Helicobacter pylori eradication: a systematic review and meta-analysis. Eur J Gastroenterol Hepatol. 2004;16:89-99.
46. Wang X, Fang JY, Lu R, Sun DF. A meta-analysis: comparison of esomeprazole and other proton pump inhibitors in eradicating Helicobacter pylori. Digestion. 2006;73:178-86.
47. Zhang G, Zou J, Liu F, Bao Z, Dong F, Huang Y, et al. The efficacy of moxifloxacin-based triple therapy in treatment of Helicobacter pylori infection: a systematic review and meta-analysis of randomized clinical trials. Braz J Med Biol Res. 2013;46:607-13.
48. Gisbert JP, Calvet X. Update on non-bismuth quadruple (concomitant) therapy for eradication of Helicobacter pylori. Clin Exp Gastroenterol. 2012;5:23-34.
49. Lv ZF, Wang FC, Zheng HL, Wang B, Xie Y, Zhou XJ, et al. Meta-analysis: is combination of tetracycline and amoxicillin suitable for Helicobacter pylori infection? World J Gastroenterol. 2015;21:2522-33.
50. Luther J, Higgins PDR, Schoenfeld PS, Moayyedi P, Vakil N, Chey WD. Empiric quadruple vs. triple therapy for primary treatment of Helicobacter pylori infection: Systematic review and meta-analysis of efficacy and tolerability. Am J Gastroenterol. 2010;105:65-73.
51. Vergara M, Vallve M, Gisbert JP, Calvet X. Meta-analysis: comparative efficacy of different proton-pump inhibitors in triple therapy for Helicobacter pylori eradication. Aliment Pharmacol Ther. 2003;18:647-54.
52. Ford AC, Malfertheiner P, Giguere M, Santana J, Khan M, Moayyedi P. Adverse events with bismuth salts for Helicobacter pylori eradication: systematic review and meta-analysis. World J Gastroenterol. 2008;14:7361-70.
53. Graham DY, Hammoud F, El-Zimaity HMT, Kim JG, Osato MS, El-Serag HB. Meta-analysis: proton pump inhibitor or H2-receptor antagonist for Helicobacter pylori eradication. Aliment Pharmacol Ther. 2003;17:1229-36.
54. Nishizawa T, Nishizawa Y, Yahagi N, Kanai T, Takahashi M, Suzuki H. Effect of supplementation with rebamipide for Helicobacter pylori eradication therapy: a systematic review and meta-analysis. J Gastroenterol Hepatol. 2014;29 Suppl 4:20-4.
55. Fock KM, Katelaris P, Sugano K, Ang TL, Hunt R, Talley NJ, et al. Second Asia-Pacific Consensus Guidelines for Helicobacter pylori infection. J Gastroenterol Hepatol. 2009;24:1587-600.
56. Hunt RH, Xiao SD, Megraud F, Leon-Barua R, Bazzoli F, van der Merwe S, et al. Helicobacter pylori in developing countries. World Gastroenterology Organisation Global Guideline. J Gastrointestin Liver Dis. 2011;20:299-304.